NTAGI
COVID-19: Second Booster Dose Not Required, Say Government Sources As India Records 134 Coronavirus Cases in Past 24 Hours
CERVAVAC: HPV Vaccine to Prevent Cervical Cancer Could Be Manufactured in India by April-May Next Year, Says Chief of Medical Panel
COVID-19 Vaccine Update: NTAGI Approves Corbevax, Covaxin for 5-12 Years Age Group, Say Sources
COVID-19 Vaccination in India: Centre to Reduce Gap Between 2nd COVID-19 Jab, Booster Dose for Those Flying Abroad, Say Sources
COVID-19 Vaccine Update: NTAGI Asks Centre To Reduce Gap Between First and Second Dose of Covishield to 8–16 Weeks Due to Omicron
NTAGI Chief Advises People Not To Take COVID-19 ‘For Granted’ As China Witnessing Surge in Infections
COVID-19 Vaccination For Children in 12-14 Years Group to Begin This Week, Say Official Sources
Corbevax COVID-19 Vaccine is Safe, Offers High Antibody Levels, Says NTAGI Chief Dr N K Arora
COVAXIN Has Shown Good Immune Response in Children During Trials, Says NTAGI Chief Dr NK Arora
Google Trends